Adocia在1型糖尿病患者中启动BC LisPram通过泵给药的1期临床试验
29 juin 2021 12h00 HE
|
Adocia SA
首次在单个泵中测试与血糖控制相关的两个关键激素，即速效胰岛素类似物和淀粉类似物的独特组合，BioChaperone® 赖脯胰岛素和普兰林肽联合制剂的安全性、药代动力学和血糖控制能力将与赖脯胰岛素进行比较 里昂, June 30, 2021 (GLOBE NEWSWIRE) -- Adocia (巴黎泛欧交易所: FR0011184241 – ADOC),...
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
29 juin 2021 12h00 HE
|
Adocia SA
For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pumpBioChaperone® Lispro and...
Ault Life Sciences™ Presents the Todd Ault #KOalz Podcast Interview with Dr. Thomas Wisniewski
01 mai 2020 09h00 HE
|
Ault Life Sciences, Inc.
NEWPORT BEACH, Cal., May 01, 2020 (GLOBE NEWSWIRE) -- Ault Life Sciences™, Inc. (“ALSI” or the “Company”), a Delaware corporation, invites everyone interested in Alzheimer’s disease to watch an...
Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman
20 nov. 2018 09h00 HE
|
Alzamend Neuro, Inc.
Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief...
Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease
29 oct. 2018 09h00 HE
|
Alzamend Neuro, Inc.
Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”)...